(6E)-9-Methyl-3-oxa-9,12-diaza-1(4,2)-pyrimidina-2,11(1,3)dibenzenacyclododecaphan-6-ene 2-hydroxypropane-1,2,3-tricarboxylate (1:1)

Catalog No. :
ACUIGL236
CAS No. :
1204918-73-9
Molecular Formula :
C29H32N4O8
Molecular Weight :
564.59

IUPAC Name:(E)-6-methyl-12-oxa-3,6-diaza-2(4,2)-pyrimidina-1,4(1,3)-dibenzenacyclododecaphan-8-ene 2-hydroxypropane-1,2,3-tricarboxylate

(6E)-9-Methyl-3-oxa-9,12-diaza-1(4,2)-pyrimidina-2,11(1,3)dibenzenacyclododecaphan-6-ene 2-hydroxypropane-1,2,3-tricarboxylate (1:1) structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
5mg98%$161.00Login to see priceInquiryInquiry
10mg98%$221.00Login to see priceInquiryInquiry
50mg98%$662.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name(6E)-9-Methyl-3-oxa-9,12-diaza-1(4,2)-pyrimidina-2,11(1,3)dibenzenacyclododecaphan-6-ene 2-hydroxypropane-1,2,3-tricarboxylate (1:1)
IUPAC Name(E)-6-methyl-12-oxa-3,6-diaza-2(4,2)-pyrimidina-1,4(1,3)-dibenzenacyclododecaphan-8-ene 2-hydroxypropane-1,2,3-tricarboxylate
Molecular FormulaC29H32N4O8
Molecular Weight564.59
SMILESC(CC(O)=O)(CC(O)=O)(C(O)=O)O.CN1CC2=CC(N=C3NC(C=4C=C(C=CC4)OCC/C=C/C1)=CC=N3)=CC=C2
InChI KeyNWYDRHSNEATNRI-SQQVDAMQSA-N
Synonym(E/Z)-Zotiraciclib citrate-TG-02 citrate;SB-1317 citrate;(E/Z)-TG02 citrate
CAS No.1204918-73-9

Synthetic Route by SureRoute

1. ACUIGL236 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACUIGL236 route product structure diagram
    ACUIGL2361204918-73-9
Inquiry

2. ACUIGL236 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACUIGL236 route product structure diagram
    ACUIGL2361204918-73-9
Inquiry

Comments (0)